China’s Venus Medtech looks south for IPO
Chinese biotechnology company Venus Medtech (Huangzhou) is seeking approval to list in Hong Kong, having filed a draft prospectus with the city’s bourse on Monday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: